A Pilot Study to Evaluate Alternative Viral Load Tests During Start of Antiretroviral Therapy
NCT05418790 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2022-06-14
Summary
A pilot study of alternative viral load testing with samples collected in the clinic and at home compared to traditional viral load monitoring in participants engaged in HIV care. Approximately 15 participants starting ART, or working to suppress a detectable viral load, will monitor viral loads during regular clinic appointments and in intermediate time-points during their participation in this pilot study.
Conditions
Interventions
- DEVICE
-
TASSO device
During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Luis Montaner
lead OTHER
Principal Investigators
-
Luis Montaner · The Wistar Institute
Study Design
- Allocation
- NA
- Purpose
- DEVICE_FEASIBILITY
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-31
- Primary Completion
- 2023-08-31
- Completion
- 2023-09-30
More Related Trials
-
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
NCT00855413 ·Status: TERMINATED ·Phase: PHASE4
-
Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment
NCT00011128 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
NCT00051831 ·Status: COMPLETED ·Phase: NA
-
Early ART to Limit Infection and Establishment of Reservoir
NCT02859558 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment
NCT00001069 ·Status: TERMINATED
-
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care
NCT01900080 ·Status: UNKNOWN ·Phase: NA
-
The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection
NCT05606055 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
NCT00749580 ·Status: COMPLETED ·Phase: NA
-
Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects
NCT01029548 ·Status: COMPLETED
-
Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen
NCT02191332 ·Status: COMPLETED
-
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
NCT00705926 ·Status: COMPLETED ·Phase: PHASE1
-
The "START" (a Streamlined ART Initiation Strategy) Study
NCT01810289 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
NCT02616029 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
NCT01968551 ·Status: COMPLETED ·Phase: PHASE3
-
Same-Day Antiretroviral Therapy Initiation
NCT04032028 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
NCT00529243 ·Status: COMPLETED ·Phase: PHASE3
-
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
NCT04388904 ·Status: COMPLETED ·Phase: PHASE4
-
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
NCT02121795 ·Status: COMPLETED ·Phase: PHASE3
-
Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
NCT01034917 ·Status: COMPLETED ·Phase: PHASE3
-
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
NCT01565850 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
NCT02269917 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
NCT00321438 ·Status: TERMINATED
-
Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)
NCT00705419 ·Status: COMPLETED
-
Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)
NCT04021290 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of Two Tests for Anti-HIV Drug Resistance
NCT00006490 ·Status: COMPLETED